Angelini Pharma acquires Arvelle Therapeutics
Angelini Pharma and Arvelle Therapeutics have agreed on the 4th January 2021 a definitive merger agreement valuing Arvelle Therapeutics at up to $960 million.
Arvelle Therapeutics is a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders and epilepsy.
This acquisition will enable Angelini Pharma to become a leading player amongst companies focused on Central Nervous System (CNS) and mental health disorder treatments.
Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Group. Angelini Pharma is committed to helping patients in the therapeutics areas of Mental Health (including Pain), Rare Diseases, and Consumer Healthcare. Moreover, Angelini Pharma US has special focus and commitment in Infection Prevention.